Pediatric allergic rhinitis: treatment.
Allergic rhinitis, an IgE-mediated disease, is the most common chronic childhood condition and is characterized by nasal sneezing, rhinorrhea, palate and eye itchiness, and congestion. Allergic rhinitis should be diagnosed as early as possible to avoid detrimental effects on the quality of life and comorbid disorders. Treatment initially involves avoidance measures and, when necessary, pharmacotherapy or immunotherapy. Pharmacotherapy generally involves antihistamines or nasal corticosteroids, but other medications such as leukotriene antagonists have demonstrated effectiveness in treating allergic rhinitis symptoms. Immunotherapy generally is reserved for patients unresponsive to therapy or unable to take medications.
Lai
Lien
L
Department of Medicine, Creighton University Medical Center, 601 North 30th Street, Suite 5850, Omaha, NE 68131 USA.
Casale
Thomas B
TB
Stokes
Jeffrey
J
D000485:Allergens / Q000276:immunology*; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D002648:Child; D018680:Cholinergic Antagonists / Q000627:therapeutic use; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006801:Humans; D020024:Leukotriene Antagonists / Q000627:therapeutic use; D014663:Nasal Decongestants / Q000627:therapeutic use; D000069444:Omalizumab; D012220:Rhinitis / Q000188:drug therapy* / Q000276:immunology*
D000485:Allergens; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018680:Cholinergic Antagonists; D006634:Histamine H1 Antagonists; D020024:Leukotriene Antagonists; D014663:Nasal Decongestants; D000069444:Omalizumab